Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs – – Phase 3 ECLIPSE registrational program in chronic hepatitis...
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of...
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore...
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24...
– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week...
– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.255 | 3.54412786657 | 7.195 | 7.56 | 7.04 | 1472245 | 7.34833923 | CS |
4 | -0.36 | -4.60947503201 | 7.81 | 9.95 | 7.025 | 1516061 | 7.98956604 | CS |
12 | -0.12 | -1.58520475561 | 7.57 | 10.44 | 6.56 | 1275080 | 8.09772852 | CS |
26 | -1.89 | -20.2355460385 | 9.34 | 11 | 6.56 | 1029275 | 8.35101404 | CS |
52 | -2.72 | -26.7453294002 | 10.17 | 13.09 | 6.56 | 1067195 | 9.19678312 | CS |
156 | -33.67 | -81.8822957198 | 41.12 | 42.54 | 6.56 | 1144903 | 17.76843691 | CS |
260 | -5.21 | -41.1532385466 | 12.66 | 141.01 | 6.56 | 1162082 | 28.10800788 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.